Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + nab-paclitaxel + iparomlimab + tuvorilimab
- Development stage
- Phase 2
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This combination therapy consists of the chemotherapy agents gemcitabine and nab-paclitaxel (the AG regimen) administered alongside two immune checkpoint inhibitors: iparomlimab (AK102), an anti-CTLA-4 monoclonal antibody, and tuvorilimab (AK127), an anti-TIGIT monoclonal antibody. The regimen is being evaluated in a Phase II clinical trial sponsored by Xinhua Hospital (Shanghai Jiao Tong University School of Medicine) for the treatment of advanced unresectable gallbladder cancer. The combination aims to enhance anti-tumor immune responses by simultaneously targeting the CTLA-4 and TIGIT pathways while utilizing the cytotoxic effects of chemotherapy to promote immunogenic cell death and improve surgical conversion rates. Both iparomlimab and tuvorilimab were developed by Akeso Bio.
- Other names
- Iparomlimab and TuvorilimabGemcitabine plus Nab-Paclitaxel in combination with Iparomlimab and Tuvorilimab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on gemcitabine + nab-paclitaxel + iparomlimab + tuvorilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + nab-paclitaxel + iparomlimab + tuvorilimab.